Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C~* Male and female subjects, 18 to 70 years of age, inclusive~* Genotype 1, chronic hepatitis C with detectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)~* Screening laboratory values, tests, and physical exam within acceptable ranges~* Able and willing to follow contraception requirements~* Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions~Exclusion Criteria~* Subject has any contraindications to Pegasys® or Copegus® therapy~* Evidence of hepatic decompensation in cirrhotic subjects~* History of organ transplant~* History of, or any current medical condition which could impact the safety of the subject in participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week (Type: PLACEBO_COMPARATOR): Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks.
- Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week (Type: EXPERIMENTAL): Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
- Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week (Type: EXPERIMENTAL): Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).